Share chart FibroGen
Extended chart
Simple chart
About FibroGen
FibroGen, Inc.- научная фармацевтическая компания, специализирующаяся на открытии, разработке и коммерциализации новых терапевтических агентов для лечения серьезных медицинских заболеваний. Компания использует глобальный подход к разработке и коммерциализации своих продуктов.Main settings
IPO date
2014-11-14
ISIN
US31572Q8087
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 1.8 | 8 |
| P/BV | -0.2896 | 0 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -14.91 | 0 |
| ROE | 24.54 | 7 |
| ROIC | -84.49 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.5132 | 10 |
| Debt/Ratio | 0.3407 | 10 |
| Debt/Equity | -2.17 | 10 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | -83.2 | 0 |
| Yield Ebitda, % | -23.55 | 0 |
| Yield EPS, % | -77.46 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 0.3085 $ | 0 $ | 0 $ | -0.16 % | 0 % | 0 % |
| Week | 0.3133 $ | 0 $ | 0 $ | -1.69 % | 0 % | 0 % |
| Month | 0.3285 $ | 0.2876 $ | 0.33 $ | -6.24 % | 0 % | 0 % |
| Three month | 0.2629 $ | 0.2522 $ | 0.3442 $ | 17.15 % | 0 % | 0 % |
| Half a year | 0.4632 $ | 0.2522 $ | 0.7724 $ | -33.51 % | 0 % | 0 % |
| Year | 0.3851 $ | 0.2522 $ | 1.26 $ | -20.02 % | 0 % | 0 % |
| 3 years | 13.55 $ | 0.2522 $ | 25.59 $ | -97.73 % | 0 % | 0 % |
| 5 years | 50.23 $ | 0.2522 $ | 55.74 $ | -99.39 % | 0 % | 0 % |
| 10 years | 26 $ | 0.2522 $ | 67.25 $ | -98.82 % | 0 % | 0 % |
| Year to date | 0.5034 $ | 0.2522 $ | 0.7724 $ | -38.82 % | 0 % | 0 % |
Insider trading
| Insider | Transaction date | Date of disclosure | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
| Wettig Thane CEO |
07.03.2024 | 11.03.2024 | Purchase | 1.91 | 95 500 | 50000 | 0 | 0.05 | link |
| Henderson Jeffrey William Director |
04.08.2023 | 08.08.2023 | Sale | 1.91 | 3 820 | 2000 | 0 | 0 | link |
| Henderson Jeffrey William Director |
11.07.2023 | 13.07.2023 | Sale | 2.69 | 5 380 | 2000 | 0 | 0 | link |
| Conterno Enrique A Chief Executive Officer |
07.07.2023 | 10.07.2023 | Sale | 2.8 | 5 264 | 1880 | 0 | 0 | link |
| EDWARDS JEFFREY L Director |
09.06.2023 | 09.06.2023 | Sale | 17.19 | 135 612 | 7889 | 0 | -0.01 | link |
| Blaug Suzanne Director |
09.06.2023 | 09.06.2023 | Sale | 17.2 | 146 544 | 8520 | 0 | -0.01 | link |
| Henderson Jeffrey William Director |
08.06.2023 | 09.06.2023 | Sale | 17.46 | 122 220 | 7000 | 0 | -0.01 | link |
| Ho Maykin Director |
08.06.2023 | 09.06.2023 | Sale | 17.44 | 148 589 | 8520 | 0 | -0.01 | link |
| Conterno Enrique A Chief Executive Officer |
07.06.2023 | 09.06.2023 | Sale | 17.04 | 151 605 | 8897 | 0 | -0.01 | link |
| Eisner Mark EVP, Chief Medical Officer |
07.06.2023 | 09.06.2023 | Sale | 17.04 | 34 796 | 2042 | 0 | 0 | link |
| Chung Christine SVP, China Operations |
07.06.2023 | 09.06.2023 | Sale | 17.04 | 61 906 | 3633 | 0 | 0 | link |
| Graham Juan Chief Financial Officer |
07.06.2023 | 09.06.2023 | Sale | 16.99 | 30 327 | 1785 | 0 | 0 | link |
| Wettig Thane Chief Commercial Officer |
07.06.2023 | 09.06.2023 | Sale | 17.04 | 29 956 | 1758 | 0 | 0 | link |
| Schoeneck James A Director |
07.06.2023 | 09.06.2023 | Sale | 18.03 | 128 013 | 7100 | 0 | -0.01 | link |
| Wettig Thane Chief Commercial Officer |
23.03.2023 | 24.03.2023 | Sale | 18.71 | 16 933 | 905 | 0 | 0 | link |
| Wettig Thane Chief Commercial Officer |
23.12.2022 | 28.12.2022 | Sale | 15.8 | 11 597 | 734 | 0 | 0 | link |
| Cotroneo Pat SVP, Finance and CFO |
15.06.2021 | 17.06.2021 | Sale | 25.62 | 103 838 | 4053 | 0 | 0 | link |
Main owners
| Institutions | Volume | Share, % |
| PRIMECAP Management Company | 14 471 928 | 14.65 |
| Armistice Capital, LLC | 9 764 000 | 9.89 |
| Blackrock Inc. | 7 205 300 | 7.29 |
| Vanguard Group Inc | 7 044 149 | 7.13 |
| Jacobs Levy Equity Management, Inc. | 2 489 506 | 2.52 |
| Acadian Asset Management. LLC | 2 468 928 | 2.5 |
| Citadel Advisors Llc | 2 390 681 | 2.42 |
| Assenagon Asset Management S.A. | 2 226 857 | 2.25 |
| Two Sigma Investments, LP | 2 101 283 | 2.13 |
| Geode Capital Management, LLC | 2 018 281 | 2.04 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Thane Wettig | CEO & Director | 807.35k | 1965 (60 years) |
| Dr. Barry A. Berkowitz Ph.D. | Founder | N/A | |
| Dr. John J. Hunter Ph.D. | Chief Scientific Officer | N/A | 1963 (62 years) |
| Ms. Christine L. Chung | Senior Vice President of China Operations | 1.27M | 1968 (57 years) |
| Mr. Michael D. Lowenstein J.D., Ph.D. | Chief Legal Officer | N/A | |
| Ms. Tricia Stewart | Chief People Officer | N/A | |
| Mr. Kirk A. Christoffersen MBA | Chief Business Officer | N/A | 1969 (56 years) |
| Dr. Rahul Rajan Kaushik Ph.D. | Senior Vice President of Pharmaceutical Development, Technical Operations & Manufacturing | N/A | |
| David DeLucia | Vice President of Corporate FP&A and Investor Relations | N/A | |
| Mr. Juan Graham | Senior VP & CFO | 1976 (49 years) |
About company
Address: United States, San Francisco, 409 Illinois Street - Open in google maps, Open in yandex maps
Website: https://www.fibrogen.com
Website: https://www.fibrogen.com
